We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+6.12%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.93B
AUM Growth
-$220M
Cap. Flow
-$774M
Cap. Flow %
-40.09%
Top 10 Hldgs %
34.72%
Holding
143
New
28
Increased
19
Reduced
29
Closed
37

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$75.2M
2
HUM icon
Humana
HUM
+$40.6M
3
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$30.6M
4
DVA icon
DaVita
DVA
+$28.5M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$25.6M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$51.8M
2
AZN icon
AstraZeneca
AZN
+$48.2M
3
ABBV icon
AbbVie
ABBV
+$45M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$35M
5
THOR
THORATEC CORPORATION
THOR
+$33.2M

Sector Composition

Rank Sector Weight
1 Healthcare 46.08%
2 Financials 1.16%
3 Technology 0.74%
4 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICAD
101
DELISTED
iCAD Inc
ICAD
– –
-38,887
Closed -$205K
IRWD icon
102
PUT
Ironwood Pharmaceuticals
IRWD
$611M
– –
-119,400
Closed -$1.18M
NVAX icon
103
Novavax
NVAX
$1.23B
– –
-53,849
Closed -$3.39M
PFE icon
104
Pfizer
PFE
$140B
– –
-1,902,470
Closed -$51.8M
SRPT icon
105
PUT
Sarepta Therapeutics
SRPT
$1.66B
– –
-100,000
Closed -$4.72M
THC icon
106
Tenet Healthcare
THC
$20.1B
– –
-788,000
Closed -$32.5M
TXMD icon
107
TherapeuticsMD
TXMD
$23.8M
– –
-25,000
Closed -$3.66M
TRAW icon
108
Traws Pharma
TRAW
$7.43M
– –
-17
Closed -$25.6M
ONCT
109
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-357
Closed -$1.01M
ESRX
110
DELISTED
Express Scripts Holding Company
ESRX
– –
-65,000
Closed -$4.02M
ARIA
111
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-1,227,204
Closed -$22.6M
SQNM
112
DELISTED
SEQUENOM INC NEW
SQNM
– –
-985,000
Closed -$2.63M
SGNT
113
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-1,014,863
Closed -$20.7M
THOR
114
DELISTED
THORATEC CORPORATION
THOR
– –
-891,000
Closed -$33.2M
CTRX
115
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
– –
-12,500
Closed -$574K
GEVA
116
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-50,000
Closed -$3.17M
PCYC
117
DELISTED
PHARMACYCLICS INC
PCYC
– –
-127,030
Closed -$17.6M
AVNR
118
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-155,000
Closed -$656K
DNDN
119
PUT
DELISTED
DENDREON CORPORATION
DNDN
– –
-700,000
Closed -$2.05M
DRTX
120
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
– –
-275,979
Closed -$2.5M
FRX
121
CALL
DELISTED
FOREST LABORATORIES INC
FRX
– –
-100,000
Closed -$4.28M
FRX
122
DELISTED
FOREST LABORATORIES INC
FRX
– –
-745,000
Closed -$31.9M
SLTM
123
DELISTED
SOLTA MED INC (DE)
SLTM
– –
-339,063
Closed -$702K
ELN
124
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
– –
-100,000
Closed -$1.56M
SPHS
125
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-123,585
Closed -$578K
2 3 4
5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2013 Portfolio in Review

As of Q4 2013, Deerfield Management held 143 positions worth $1.93B, down 10% from $2.15B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $774M in Q4 2013, closing 37 positions and reducing 29 holdings. Its most notable exit was Pfizer, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Humana worth $42.8M.

  • Deerfield Management's largest Q4 2013 buy was Humana: 414,670 shares worth $42.8M.
  • Deerfield Management added most to QUESTCOR PHARMA INC in Q4 2013, an estimated $75.2M increase.
  • Deerfield Management's biggest Q4 2013 reduction was Teva Pharmaceuticals, cutting an estimated $35M.
  • Deerfield Management fully exited Pfizer in Q4 2013, selling an estimated $51.8M.
  • Deerfield Management's ten largest holdings make up 35% of its $1.93B portfolio in Q4 2013.
  • Deerfield Management opened 28 new positions and closed 37 in Q4 2013.
  • Deerfield Management's portfolio value fell 10% quarter-over-quarter to $1.93B.

Based on Deerfield Management's 13F filing for Q4 2013, filed 14 Feb 2014.